RhumbLine Advisers
CAMP icon

RhumbLine Advisers’s CAMP4 Therapeutics CAMP Stock Holding History

RhumbLine Advisers’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Buy
+24,227
New +$104K ﹤0.01% 3512
2025
Q2 		– Sell
-5,820
Closed -$23.3K – 4158
2025
Q1 		$23.3K Sell
5,820
-43,969
-88% -$213K ﹤0.01% 3715
2024
Q4 		$260K Buy
+49,789
New +$409K ﹤0.01% 3074

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's CAMP Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in CAMP4 Therapeutics (CAMP) in Q2 2026: 24,227 shares worth $106K. The stake represents ﹤0.01% of the portfolio and ranks #3512 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in CAMP as recently as Q1 2025.

RhumbLine Advisers first reported a position in CAMP in Q4 2024 and has held it in 3 quarters since. The position peaked at $260K in Q4 2024. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • RhumbLine Advisers held 24,227 shares of CAMP4 Therapeutics worth $106K as of Q2 2026.
  • CAMP4 Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • CAMP4 Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3512 holding.
  • RhumbLine Advisers first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • RhumbLine Advisers's CAMP4 Therapeutics position peaked at $260K in Q4 2024.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.